In October 2023, Sanofi inked a potential $1.5 billion partnership with Teva Pharmaceuticals to develop TEV’574, an investigational anti-TL1A agent being studied for ulcerative colitis and Crohn’s ...
Pipeline developments are expected to play a crucial role in Teva’s future. The upcoming Phase 2 top-line results for Anti-TL1A in Q4 2024 and the advancement of Duvakitug’s subcutaneous formulation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback